

Laurence Zitvogel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7945198/publications.pdf>

Version: 2024-02-01

429
papers

99,806
citations

518

131
h-index

293

301
g-index

452
all docs

452
docs citations

452
times ranked

87527
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of the ileal microbiota on colon cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 955-966.	4.3	11
2	Immunogenic cell stress and death. <i>Nature Immunology</i> , 2022, 23, 487-500.	7.0	434
3	Intestinal <i>Akkermansia muciniphila</i> predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	15.2	225
4	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. <i>Nature Medicine</i> , 2022, 28, 535-544.	15.2	158
5	Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics. <i>Cell Metabolism</i> , 2022, 34, 350-352.	7.2	7
6	A probiotic supplement boosts response to cancer immunotherapy. <i>Nature Medicine</i> , 2022, 28, 633-634.	15.2	5
7	Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. , 2022, 10, e004191.		23
8	Cross-reactivity between microbial and tumor antigens. <i>Current Opinion in Immunology</i> , 2022, 75, 102171.	2.4	16
9	Cancer Induces a Stress Ileopathy Depending on β -Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. <i>Cancer Discovery</i> , 2022, 12, 1128-1151.	7.7	44
10	Targeting the gut and tumor microbiota in cancer. <i>Nature Medicine</i> , 2022, 28, 690-703.	15.2	159
11	Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. <i>Oncolimmunology</i> , 2022, 11, .	2.1	9
12	Boosting the immunotherapy response by nutritional interventions. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	8
13	PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. <i>Oncolimmunology</i> , 2022, 11, .	2.1	25
14	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021, 11, 408-423.	7.7	28
15	Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. <i>Cell Death and Differentiation</i> , 2021, 28, 1532-1547.	5.0	11
16	Immunomodulation by targeted anticancer agents. <i>Cancer Cell</i> , 2021, 39, 310-345.	7.7	131
17	Cross-reactivity between cancer and microbial antigens. <i>Oncolimmunology</i> , 2021, 10, 1877416.	2.1	20
18	Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. <i>JCI Insight</i> , 2021, 6, .	2.3	143

#	ARTICLE	IF	CITATIONS
19	Lower Airway Dysbiosis Exacerbates Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 224-226.	7.7	12
20	Immune checkpoint inhibitors. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	27
21	The microbiome and human cancer. <i>Science</i> , 2021, 371, .	6.0	506
22	Oral administration of <i>Akkermansia muciniphila</i> elevates systemic antiaging and anticancer metabolites. <i>Aging</i> , 2021, 13, 6375-6405.	1.4	75
23	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021, 12, 258.	2.7	113
24	Subversion of calreticulin exposure as a strategy of immune escape. <i>Cancer Cell</i> , 2021, 39, 449-451.	7.7	7
25	Beneficial autoimmunity improves cancer prognosis. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 591-602.	12.5	63
26	Bortezomib Induces Immunogenic Cell Death in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2021, 2, 405-407.	2.6	11
27	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021, 28, 2778-2796.	5.0	72
28	Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 178.	7.1	3
29	Multifaceted modes of action of the anticancer probiotic <i>Enterococcus hirae</i> . <i>Cell Death and Differentiation</i> , 2021, 28, 2276-2295.	5.0	18
30	Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index. <i>Cell Death and Disease</i> , 2021, 12, 599.	2.7	13
31	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216
32	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021, 28, 3297-3315.	5.0	31
33	Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. <i>Cancer Discovery</i> , 2021, 11, 2396-2412.	7.7	81
34	Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. <i>Immunity</i> , 2021, 54, 1883-1900.e5.	6.6	233
35	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	20
36	Circulating acetylated polyamines correlate with Covid-19 severity in cancer patients. <i>Aging</i> , 2021, 13, 20860-20885.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Commensals shape the immune system. <i>Nature Reviews Immunology</i> , 2021, 21, 615-615.	10.6	1
38	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , 2021, 15, 2507-2543.	2.1	7
39	A genotype-phenotype screening system using conditionally immortalized immature dendritic cells. <i>STAR Protocols</i> , 2021, 2, 100732.	0.5	10
40	Immunodynamics of explanted human tumors for immuno-oncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	3.3	9
41	Harnessing the microbiome to restore immunotherapy response. <i>Nature Cancer</i> , 2021, 2, 1301-1304.	5.7	10
42	Oncolysis without viruses inducing systemic anticancer immune responses with local therapies. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 49-64.	12.5	92
43	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. <i>Molecular Cell</i> , 2020, 77, 748-760.e9.	4.5	77
44	The immuno-oncological challenge of COVID-19. <i>Nature Cancer</i> , 2020, 1, 946-964.	5.7	96
45	Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?. <i>Nature Reviews Immunology</i> , 2020, 20, 522-528.	10.6	54
46	Trial watch: STING agonists in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1777624.	2.1	148
47	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1777625.	2.1	91
48	Turning tolerogenic into immunogenic ileal cell death through ileal microbiota: the key to unlock the mystery of colon cancer immunoscore?. <i>Oncolmmunology</i> , 2020, 9, 1778834.	2.1	1
49	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 725-741.	12.5	701
50	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1243-1250.	1.6	154
51	Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. <i>Oncolmmunology</i> , 2020, 9, 1795995.	2.1	29
52	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3819.	5.8	71
53	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020, 182, 1401-1418.e18.	13.5	663
54	Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination. <i>Cancer Discovery</i> , 2020, 10, 1097-1099.	7.7	7

#	ARTICLE	IF	CITATIONS
55	Inosine: novel microbiota-derived immunostimulatory metabolite. <i>Cell Research</i> , 2020, 30, 942-943.	5.7	14
56	Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. <i>Oncolmunology</i> , 2020, 9, 1794423.	2.1	7
57	Immune responses during COVID-19 infection. <i>Oncolmunology</i> , 2020, 9, 1807836.	2.1	103
58	Antibiotics impair immunotherapy for urothelial cancer. <i>Nature Reviews Urology</i> , 2020, 17, 605-606.	1.9	4
59	On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. <i>Cell Death and Disease</i> , 2020, 11, 656.	2.7	40
60	Cross-reactivity between tumor MHC class II-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942.	6.0	217
61	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. <i>Frontiers in Immunology</i> , 2020, 11, 600886.	2.2	43
62	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy – Achieving global consensus and visibility for cellular host-directed therapies. <i>International Journal of Infectious Diseases</i> , 2020, 96, 431-439.	1.5	43
63	COVID-19: a challenge for oncology services. <i>Oncolmunology</i> , 2020, 9, 1760686.	2.1	7
64	CD4+ T Cells at the Center of Inflammaging. <i>Cell Metabolism</i> , 2020, 32, 4-5.	7.2	16
65	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , 2020, 78, 195-206.	0.9	192
66	Seeking Cellular Fitness and Immune Evasion: Autophagy in Pancreatic Carcinoma. <i>Cancer Cell</i> , 2020, 37, 759-760.	7.7	7
67	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. <i>Oncolmunology</i> , 2020, 9, 1774298.	2.1	22
68	Trial watch: TLR3 agonists in cancer therapy. <i>Oncolmunology</i> , 2020, 9, 1771143.	2.1	116
69	Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. <i>Oncolmunology</i> , 2020, 9, 1789284.	2.1	4
70	Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. <i>Oncolmunology</i> , 2020, 9, 1677427.	2.1	8
71	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. <i>Oncolmunology</i> , 2020, 9, 1703449.	2.1	156
72	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610

#	ARTICLE	IF	CITATIONS
73	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , 2020, 26, 919-931.	15.2	118
74	Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3095.	0.8	17
75	Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. <i>EMBO Molecular Medicine</i> , 2020, 12, e11622.	3.3	67
76	Contribution of annexin A1 to anticancer immunosurveillance. <i>Oncolmmunology</i> , 2019, 8, e1647760.	2.1	27
77	Trial watch: dendritic cell vaccination for cancer immunotherapy. <i>Oncolmmunology</i> , 2019, 8, 1638212.	2.1	125
78	Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade. <i>Oncolmmunology</i> , 2019, 8, e1637188.	2.1	61
79	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019, 29, 846-861.	5.7	160
80	Stressâ€“glucocorticoidâ€“TSC22D3 axis compromises therapy-induced antitumor immunity. <i>Nature Medicine</i> , 2019, 25, 1428-1441.	15.2	185
81	Leptin-Producing Oncolytic Virus Makes Tumor-Infiltrating T Cells Fit, Not Fat. <i>Immunity</i> , 2019, 51, 423-425.	6.6	4
82	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncolmmunology</i> , 2019, 8, e1657375.	2.1	56
83	Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. <i>Oncolmmunology</i> , 2019, 8, e1660121.	2.1	4
84	Interferon- β induces cancer cell ferroptosis. <i>Cell Research</i> , 2019, 29, 692-693.	5.7	28
85	Tumor lysis with LTX-401 creates anticancer immunity. <i>Oncolmmunology</i> , 2019, 8, e1594555.	2.1	26
86	A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers. <i>Oncolmmunology</i> , 2019, 8, 1606665.	2.1	12
87	Trial watch: dietary interventions for cancer therapy. <i>Oncolmmunology</i> , 2019, 8, e1591878.	2.1	52
88	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 1486.	5.8	189
89	Failure of immunosurveillance accelerates aging. <i>Oncolmmunology</i> , 2019, 8, e1575117.	2.1	9
90	Immunostimulatory gut bacteria. <i>Science</i> , 2019, 366, 1077-1078.	6.0	17

#	ARTICLE	IF	CITATIONS
91	Anticancer effects of anti-CD47 immunotherapy <i>in vivo</i> . <i>Oncolmmunology</i> , 2019, 8, 1550619.	2.1	32
92	Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. <i>Oncolmmunology</i> , 2019, 8, e1498285.	2.1	25
93	PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. <i>British Journal of Cancer</i> , 2019, 120, 3-5.	2.9	87
94	The intimate relationship between gut microbiota and cancer immunotherapy. <i>Gut Microbes</i> , 2019, 10, 424-428.	4.3	98
95	CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancerâ€“Draining Lymph Nodes. <i>Cancer Immunology Research</i> , 2019, 7, 208-218.	1.6	32
96	The impact of the intestinal microbiota in therapeutic responses against cancer. <i>Comptes Rendus - Biologies</i> , 2018, 341, 284-289.	0.1	65
97	The gut microbiota influences anticancer immunosurveillance and general health. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 382-396.	12.5	389
98	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolmmunology</i> , 2018, 7, e1433982.	2.1	38
99	The breakthrough of the microbiota. <i>Nature Reviews Immunology</i> , 2018, 18, 87-88.	10.6	112
100	eIF2Î± phosphorylation is pathognomonic for immunogenic cell death. <i>Cell Death and Differentiation</i> , 2018, 25, 1375-1393.	5.0	162
101	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018, 25, 486-541.	5.0	4,036
102	The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. <i>Oncolmmunology</i> , 2018, 7, e1434468.	2.1	51
103	The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. <i>Science</i> , 2018, 359, 1366-1370.	6.0	525
104	Gut microbiome influences efficacy of PD-1â€“based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	6.0	3,689
105	TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. <i>Oncolmmunology</i> , 2018, 7, e1386826.	2.1	26
106	A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. <i>Cancer Research</i> , 2018, 78, 1003-1016.	0.4	269
107	Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 2480.	2.2	57
108	Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. <i>Cell Death and Disease</i> , 2018, 9, 1086.	2.7	20

#	ARTICLE	IF	CITATIONS
109	Trial Watch: Toll-like receptor agonists in cancer immunotherapy. <i>Oncolimmunology</i> , 2018, 7, e1526250.	2.1	172
110	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolimmunology</i> , 2018, 7, e1511506.	2.1	121
111	TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. <i>Oncolimmunology</i> , 2018, 7, e1462431.	2.1	82
112	Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. <i>Oncolimmunology</i> , 2018, 7, e1484980.	2.1	24
113	Reply to "Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma". <i>Nature Communications</i> , 2018, 9, 2922.	5.8	3
114	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. <i>Oncolimmunology</i> , 2018, 7, e1503032.	2.1	67
115	Anticorps monoclonaux en oncologie : déclencher une réponse immunitaire en plus de la réduction tumorale spécifique.. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 707-735.	0.0	0
116	Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. <i>Oncolimmunology</i> , 2017, 6, e1132137.	2.1	45
117	NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. <i>Oncolimmunology</i> , 2017, 6, e1137418.	2.1	42
118	Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. <i>Oncolimmunology</i> , 2017, 6, e1163456.	2.1	30
119	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. <i>Oncolimmunology</i> , 2017, 6, e1299303.	2.1	20
120	Pro-necrotic molecules impact local immunosurveillance in human breast cancer. <i>Oncolimmunology</i> , 2017, 6, e1299302.	2.1	88
121	Trial watch: Dendritic cell-based anticancer immunotherapy. <i>Oncolimmunology</i> , 2017, 6, e1328341.	2.1	87
122	Anticancer effects of the microbiome and its products. <i>Nature Reviews Microbiology</i> , 2017, 15, 465-478.	13.6	399
123	Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAF ^{V600E} Melanoma Lines with Vemurafenib. <i>Cancer Immunology Research</i> , 2017, 5, 582-593.	1.6	17
124	Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN- γ Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. <i>Cancer Research</i> , 2017, 77, 4146-4157.	0.4	107
125	The complement system is also important in immunogenic cell death. <i>Nature Reviews Immunology</i> , 2017, 17, 143-143.	10.6	6
126	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. <i>Oncolimmunology</i> , 2017, 6, e1386829.	2.1	209

#	ARTICLE	IF	CITATIONS
127	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017, 280, 165-174.	2.8	82
128	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. <i>Oncolmunology</i> , 2017, 6, e1371896.	2.1	36
129	Trial watch: Immune checkpoint blockers for cancer therapy. <i>Oncolmunology</i> , 2017, 6, e1373237.	2.1	62
130	Nutrition, inflammation and cancer. <i>Nature Immunology</i> , 2017, 18, 843-850.	7.0	313
131	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 717-734.	12.5	1,590
132	Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. <i>Nature Immunology</i> , 2017, 18, 1004-1015.	7.0	504
133	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. <i>Oncolmunology</i> , 2017, 6, e1363139.	2.1	60
134	Trial watch: DNA-based vaccines for oncological indications. <i>Oncolmunology</i> , 2017, 6, e1398878.	2.1	30
135	Identification of pharmacological agents that induce HMGB1 release. <i>Scientific Reports</i> , 2017, 7, 14915.	1.6	37
136	Immunogenic cell death in cancer and infectious disease. <i>Nature Reviews Immunology</i> , 2017, 17, 97-111.	10.6	2,000
137	Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 462-462.	0.8	28
138	Extracellular vesicles: masters of intercellular communication and potential clinical interventions. <i>Journal of Clinical Investigation</i> , 2016, 126, 1139-1143.	3.9	375
139	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016, 30, 147-160.	7.7	410
140	Immunological off-target effects of imatinib. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 431-446.	12.5	120
141	Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. <i>Oncolmunology</i> , 2016, 5, e1118600.	2.1	14
142	NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution. <i>Oncolmunology</i> , 2016, 5, e1154251.	2.1	20
143	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. <i>Oncolmunology</i> , 2016, 5, e1160193.	2.1	11
144	STAT3 inhibition for cancer therapy: Cell-autonomous effects only?. <i>Oncolmunology</i> , 2016, 5, e1126063.	2.1	12

#	ARTICLE	IF	CITATIONS
145	Positive impact of autophagy in human breast cancer cells on local immunosurveillance. <i>Oncolmmunology</i> , 2016, 5, e1174801.	2.1	10
146	Microbiome and Anticancer Immunosurveillance. <i>Cell</i> , 2016, 165, 276-287.	13.5	366
147	Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. <i>Cancer Cell</i> , 2016, 29, 587-601.	7.7	375
148	The oncolytic compound LTX-401 targets the Golgi apparatus. <i>Cell Death and Differentiation</i> , 2016, 23, 2031-2041.	5.0	25
149	Mouse models in oncoimmunology. <i>Nature Reviews Cancer</i> , 2016, 16, 759-773.	12.8	267
150	Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. <i>Oncolmmunology</i> , 2016, 5, e1220467.	2.1	88
151	<i>Enterococcus hirae</i> and <i>Barnesiella intestinihominis</i> Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , 2016, 45, 931-943.	6.6	645
152	Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. <i>Cancer Research</i> , 2016, 76, 4602-4607.	0.4	92
153	The ratio of CD8 ⁺ /FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma <i>in situ</i> . <i>Oncolmmunology</i> , 2016, 5, e1218106.	2.1	50
154	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolmmunology</i> , 2016, 5, e1214790.	2.1	64
155	Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 895-902.	1.6	134
156	Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. <i>Cancer Research</i> , 2016, 76, 3122-3126.	0.4	47
157	Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. <i>Oncolmmunology</i> , 2016, 5, e1177692.	2.1	52
158	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. <i>Immunity</i> , 2016, 44, 1255-1269.	6.6	797
159	Unchaining NK cell-mediated anticancer immunosurveillance. <i>Nature Immunology</i> , 2016, 17, 746-747.	7.0	1
160	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
161	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1139275.	2.1	21
162	Trial Watch-Immunostimulation with cytokines in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1115942.	2.1	52

#	ARTICLE	IF	CITATIONS
163	Prime time for immune-checkpoint targeted therapy at ASCO 2015. <i>Oncolmmunology</i> , 2016, 5, e1068494.	2.1	8
164	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016, 12, 864-875.	4.3	90
165	Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. <i>Oncolmmunology</i> , 2016, 5, e1064581.	2.1	14
166	Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 994-1001.	0.3	27
167	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. <i>Immunity</i> , 2016, 44, 343-354.	6.6	767
168	Trial Watch“Oncolytic viruses and cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1117740.	2.1	88
169	Therapy-induced microenvironmental changes in cancer. <i>Journal of Molecular Medicine</i> , 2016, 94, 497-508.	1.7	19
170	Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. <i>Oncolmmunology</i> , 2016, 5, e1149673.	2.1	136
171	Trial Watch“Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1149674.	2.1	46
172	Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. <i>Oncolmmunology</i> , 2016, 5, e1082706.	2.1	45
173	Improvement of immunogenic chemotherapy by STAT3 inhibition. <i>Oncolmmunology</i> , 2016, 5, e1078061.	2.1	15
174	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1088631.	2.1	104
175	Differences in the composition of the immune infiltrate in breast cancer, colorectal carcinoma, melanoma and non-small cell lung cancer: A microarray-based meta-analysis. <i>Oncolmmunology</i> , 2016, 5, e1067746.	2.1	10
176	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. <i>Oncolmmunology</i> , 2016, 5, e1071008.	2.1	545
177	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 921-937.	3.9	71
178	Dendritic cell“derived exosomes for cancer therapy. <i>Journal of Clinical Investigation</i> , 2016, 126, 1224-1232.	3.9	427
179	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	2.2	317
180	Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. <i>PLoS ONE</i> , 2015, 10, e0133363.	1.1	14

#	ARTICLE	IF	CITATIONS
181	Type I interferons in anticancer immunity. <i>Nature Reviews Immunology</i> , 2015, 15, 405-414.	10.6	929
182	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. <i>Cancer Cell</i> , 2015, 28, 690-714.	7.7	1,205
183	The oncolytic peptide LTX-315 triggers necrotic cell death. <i>Cell Cycle</i> , 2015, 14, 3506-3512.	1.3	30
184	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolmunology</i> , 2015, 4, e985940.	2.1	47
185	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmunology</i> , 2015, 4, e974411.	2.1	97
186	Microbiota Modulation of Myeloid Cells in Cancer Therapy. <i>Cancer Immunology Research</i> , 2015, 3, 103-109.	1.6	31
187	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	5.7	143
188	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. <i>Cancer Research</i> , 2015, 75, 3800-3811.	0.4	201
189	A p53-regulated immune checkpoint relevant to cancer. <i>Science</i> , 2015, 349, 476-477.	6.0	27
190	STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. <i>Cancer Research</i> , 2015, 75, 3812-3822.	0.4	85
191	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolmunology</i> , 2015, 4, e1008814.	2.1	102
192	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmunology</i> , 2015, 4, e1008866.	2.1	237
193	Antibodies regulate antitumour immunity. <i>Nature</i> , 2015, 521, 35-37.	13.7	29
194	Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. <i>Science Translational Medicine</i> , 2015, 7, 283ra55.	5.8	120
195	Cancer and the gut microbiota: An unexpected link. <i>Science Translational Medicine</i> , 2015, 7, 271ps1.	5.8	358
196	Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies. <i>Seminars in Oncology</i> , 2015, 42, 448-458.	0.8	22
197	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015, 350, 1079-1084.	6.0	2,539
198	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015, 350, 972-978.	6.0	367

#	ARTICLE	IF	CITATIONS
199	Natural and therapy-induced immunosurveillance in breast cancer. <i>Nature Medicine</i> , 2015, 21, 1128-1138.	15.2	268
200	Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. <i>Oncolmmunology</i> , 2015, 4, e1058597.	2.1	62
201	Subversion of anticancer immunosurveillance by radiotherapy. <i>Nature Immunology</i> , 2015, 16, 1005-1007.	7.0	35
202	Natural killer cell mediated immunosurveillance of pediatric neuroblastoma. <i>Oncolmmunology</i> , 2015, 4, e1042202.	2.1	31
203	Trial Watch: Adoptive cell transfer for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1046673.	2.1	29
204	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e1026531.	2.1	26
205	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015, 11, 1878-1890.	4.3	91
206	The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. <i>European Journal of Immunology</i> , 2015, 45, 17-31.	1.6	229
207	Immune infiltrate in cancer. <i>Aging</i> , 2015, 7, 358-359.	1.4	9
208	Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. <i>Oncotarget</i> , 2015, 6, 11894-11909.	0.8	39
209	Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. <i>Oncotarget</i> , 2015, 6, 20840-20850.	0.8	50
210	The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. <i>Oncotarget</i> , 2015, 6, 26599-26614.	0.8	42
211	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e988042.	2.1	27
212	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
213	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
214	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e29179.	2.1	76
215	Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress. <i>Oncolmmunology</i> , 2014, 3, e28276.	2.1	27
216	Trial Watch: Radioimmunotherapy for oncological indications. <i>Oncolmmunology</i> , 2014, 3, e954929.	2.1	40

#	ARTICLE	IF	CITATIONS
217	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e28185.	2.1	36
218	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolimmunology</i> , 2014, 3, e957994.	2.1	223
219	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27297.	2.1	99
220	Trial Watch:. <i>Oncolimmunology</i> , 2014, 3, e28694.	2.1	95
221	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. <i>Oncolimmunology</i> , 2014, 3, e28473.	2.1	112
222	Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. <i>Oncolimmunology</i> , 2014, 3, e27884.	2.1	74
223	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. <i>Oncolimmunology</i> , 2014, 3, e27560.	2.1	38
224	Mature Cytotoxic CD56 ^{bright} /CD16 ⁺ Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma. <i>Cancer Research</i> , 2014, 74, 81-92.	0.4	85
225	Regulation of CD4 ⁺ NKG2D ⁺ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15R α and NKG2D Triggering. <i>Cancer Research</i> , 2014, 74, 68-80.	0.4	43
226	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolimmunology</i> , 2014, 3, e963424.	2.1	62
227	Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy. <i>Oncolimmunology</i> , 2014, 3, e27663.	2.1	35
228	CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy. <i>Cancer Research</i> , 2014, 74, 436-445.	0.4	118
229	An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. <i>Oncolimmunology</i> , 2014, 3, e944047.	2.1	68
230	Why should we need the gut microbiota to respond to cancer therapies?. <i>Oncolimmunology</i> , 2014, 3, e27574.	2.1	17
231	CD103 ⁺ Dendritic Cells Producing Interleukin-12 in Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2014, 26, 591-593.	7.7	38
232	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27878.	2.1	134
233	Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma. <i>Cancer Research</i> , 2014, 74, 7298-7308.	0.4	96
234	Targeting Foxp1 for Reinstating Anticancer Immunosurveillance. <i>Immunity</i> , 2014, 41, 345-347.	6.6	3

#	ARTICLE	IF	CITATIONS
235	Cancer cellâ€™s autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309.	15.2	823
236	Dendritic Cellâ€™s Derived Exosomes as Immunotherapies in the Fight against Cancer. <i>Journal of Immunology</i> , 2014, 193, 1006-1011.	0.4	231
237	Trial Watch. <i>OncolImmunology</i> , 2014, 3, e28344.	2.1	31
238	Cell-Death-Associated Molecular Patterns As Determinants of Cancer Immunogenicity. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1098-1116.	2.5	36
239	Cytokines reinstate NK cellâ€™s mediated cancer immunosurveillance. <i>Journal of Clinical Investigation</i> , 2014, 124, 4687-4689.	3.9	6
240	Autophagy and Cellular Immune Responses. <i>Immunity</i> , 2013, 39, 211-227.	6.6	359
241	Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2013, 73, 3499-3510.	0.4	277
242	The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide. <i>Science</i> , 2013, 342, 971-976.	6.0	1,580
243	Lung cancer: potential targets for immunotherapy. <i>Lancet Respiratory Medicine</i> , 2013, 1, 551-563.	5.2	69
244	Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. <i>Immunity</i> , 2013, 39, 74-88.	6.6	739
245	Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?. <i>Science</i> , 2013, 339, 286-291.	6.0	943
246	Mucosal Imprinting of Vaccine-Induced CD8 ⁺ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors. <i>Science Translational Medicine</i> , 2013, 5, 172ra20.	5.8	195
247	Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells. <i>Immunity</i> , 2013, 38, 729-741.	6.6	572
248	Immunogenic Cell Death in Cancer Therapy. <i>Annual Review of Immunology</i> , 2013, 31, 51-72.	9.5	2,489
249	Crosstalk between ER stress and immunogenic cell death. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 311-318.	3.2	177
250	Trial watch. <i>OncolImmunology</i> , 2013, 2, e23803.	2.1	92
251	Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients. <i>OncolImmunology</i> , 2013, 2, e23079.	2.1	18
252	Phase I clinical trial combining imatinib mesylate and IL-2. <i>OncolImmunology</i> , 2013, 2, e23080.	2.1	29

#	ARTICLE	IF	CITATIONS
253	Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab. <i>Cancer Research</i> , 2013, 73, 4663-4673.	0.4	36
254	An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. <i>Oncolmmunology</i> , 2013, 2, e22409.	2.1	20
255	ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. <i>Oncolmmunology</i> , 2013, 2, e24568.	2.1	75
256	Victories and deceptions in tumor immunology. <i>Oncolmmunology</i> , 2013, 2, e23687.	2.1	43
257	Correction: Cutting Edge: Fc γ RIII (CD16) and Fc γ RI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. <i>Journal of Immunology</i> , 2013, 190, 1381-1381.	0.4	0
258	NCR3/NKp30 Contributes to Pathogenesis in Primary Sjögren's Syndrome. <i>Science Translational Medicine</i> , 2013, 5, 195ra96.	5.8	99
259	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e23082.	2.1	130
260	Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. <i>Oncolmmunology</i> , 2013, 2, e23472.	2.1	22
261	Immunological effects of chemotherapy in spontaneous breast cancers. <i>Oncolmmunology</i> , 2013, 2, e27158.	2.1	17
262	Following up tumor-specific regulatory T cells in cancer patients. <i>Oncolmmunology</i> , 2013, 2, e25444.	2.1	21
263	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e25771.	2.1	150
264	Trial Watch: Lenalidomide-based immunochemotherapy. <i>Oncolmmunology</i> , 2013, 2, e26494.	2.1	50
265	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e22789.	2.1	92
266	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e23510.	2.1	153
267	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e26621.	2.1	101
268	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e24238.	2.1	58
269	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e24850.	2.1	49
270	Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. <i>Oncolmmunology</i> , 2013, 2, e24786.	2.1	23

#	ARTICLE	IF	CITATIONS
271	Trial Watch. <i>Oncolimmunology</i> , 2013, 2, e25238.	2.1	132
272	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e24612.	2.1	175
273	Natural killer cells in non-hematopoietic malignancies. <i>Frontiers in Immunology</i> , 2012, 3, 395.	2.2	27
274	Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. <i>Autophagy</i> , 2012, 8, 1175-1184.	4.3	69
275	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>Oncolimmunology</i> , 2012, 1, 894-907.	2.1	194
276	Abscopal but desirable. <i>Oncolimmunology</i> , 2012, 1, 407-408.	2.1	53
277	Loss-of-function alleles of <i>P2RX7</i> and <i>TLR4</i> fail to affect the response to chemotherapy in non-small cell lung cancer. <i>Oncolimmunology</i> , 2012, 1, 271-278.	2.1	36
278	Can the exome and the immunome converge on the design of efficient cancer vaccines?. <i>Oncolimmunology</i> , 2012, 1, 579-580.	2.1	22
279	Anticancer activity of cardiac glycosides. <i>Oncolimmunology</i> , 2012, 1, 1640-1642.	2.1	89
280	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. <i>Oncolimmunology</i> , 2012, 1, 326-333.	2.1	95
281	The European Academy of Tumor Immunology: Bridging fields, continents and generations. <i>Oncolimmunology</i> , 2012, 1, 127-128.	2.1	0
282	Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. <i>Oncolimmunology</i> , 2012, 1, 393-395.	2.1	58
283	Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. <i>Autophagy</i> , 2012, 8, 413-415.	4.3	90
284	Cutting Edge: Fc γ RIII (CD16) and Fc γ RI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. <i>Journal of Immunology</i> , 2012, 189, 5513-5517.	0.4	34
285	Trial Watch. <i>Oncolimmunology</i> , 2012, 1, 699-739.	2.1	184
286	Reply to: Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. <i>Nature Medicine</i> , 2012, 18, 346-346.	15.2	8
287	Targeting PD-1/PD-L1 interactions for cancer immunotherapy. <i>Oncolimmunology</i> , 2012, 1, 1223-1225.	2.1	315
288	Trial Watch. <i>Oncolimmunology</i> , 2012, 1, 306-315.	2.1	70

#	ARTICLE	IF	CITATIONS
289	Oncolmmunology: a new journal at the frontier between oncology and immunology. Oncolmmunology, 2012, 1, 1-2.	2.1	23
290	Trial Watch. Oncolmmunology, 2012, 1, 493-506.	2.1	86
291	IKDCs or B220+ NK cells are pre-mNK cells. Blood, 2012, 119, 4345-4346.	0.6	12
292	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	2.9	122
293	The secret ally: immunostimulation by anticancer drugs. Nature Reviews Drug Discovery, 2012, 11, 215-233.	21.5	591
294	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. Science, 2012, 337, 1678-1684.	6.0	367
295	Trial watch. Oncolmmunology, 2012, 1, 1111-1134.	2.1	152
296	Trial Watch: Monoclonal antibodies in cancer therapy. Oncolmmunology, 2012, 1, 28-37.	2.1	103
297	Trial watch. Oncolmmunology, 2012, 1, 1323-1343.	2.1	203
298	Inflammasomes in carcinogenesis and anticancer immune responses. Nature Immunology, 2012, 13, 343-351.	7.0	525
299	Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death. Science Translational Medicine, 2012, 4, 143ra99.	5.8	367
300	Cancer-Induced Immunosuppression: IL-18 Elicited Immunoablative NK Cells. Cancer Research, 2012, 72, 2757-2767.	0.4	95
301	Recent successes of cancer immunotherapy: a new dimension in personalized medicine?. Targeted Oncology, 2012, 7, 1-2.	1.7	5
302	TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer. Cancer Research, 2011, 71, 1607-1614.	0.4	105
303	Homeostatic defects in interleukin 18 deficient mice contribute to protection against the lethal effects of endotoxin. Immunology and Cell Biology, 2011, 89, 739-746.	1.0	17
304	Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice. Science, 2011, 334, 1573-1577.	6.0	1,159
305	Contribution of IL-17 producing T cells to the efficacy of anticancer chemotherapy. Journal of Experimental Medicine, 2011, 208, 491-503.	4.2	303
306	Innate or Adaptive Immunity? The Example of Natural Killer Cells. Science, 2011, 331, 44-49.	6.0	2,234

#	ARTICLE	IF	CITATIONS
307	Immune parameters affecting the efficacy of chemotherapeutic regimens. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 151-160.	12.5	592
308	Harnessing dendritic cells in cancer. <i>Seminars in Immunology</i> , 2011, 23, 42-49.	2.7	53
309	How to improve the immunogenicity of chemotherapy and radiotherapy. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 71-82.	2.7	72
310	Anticancer effects of imatinib via immunostimulation. <i>Nature Medicine</i> , 2011, 17, 1050-1051.	15.2	23
311	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011, 2, 66.	2.2	9
312	Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 351-358.	1.0	75
313	Antibody co-targeting of DCs. <i>Blood</i> , 2011, 118, 6726-6727.	0.6	2
314	Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. <i>Nature Medicine</i> , 2011, 17, 700-707.	15.2	282
315	IL-18 Induces PD-1-Dependent Immunosuppression in Cancer. <i>Cancer Research</i> , 2011, 71, 5393-5399.	0.4	307
316	Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 61-69.	2.7	250
317	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. <i>Seminars in Immunopathology</i> , 2011, 33, 369-383.	2.8	265
318	The dendritic cell-tumor cross-talk in cancer. <i>Current Opinion in Immunology</i> , 2011, 23, 146-152.	2.4	78
319	An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpes viridae. <i>Cell Cycle</i> , 2011, 10, 118-126.	1.3	10
320	Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients. <i>Cancer Research</i> , 2011, 71, 661-665.	0.4	144
321	Cutting Edge: Crucial Role of IL-1 and IL-23 in the Innate IL-17 Response of Peripheral Lymph Node NK1.1 ⁺ Invariant NKT Cells to Bacteria. <i>Journal of Immunology</i> , 2011, 186, 662-666.	0.4	137
322	Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors. <i>Cancer Research</i> , 2011, 71, 4809-4820.	0.4	302
323	IKK connects autophagy to major stress pathways. <i>Autophagy</i> , 2010, 6, 189-191.	4.3	46
324	Bacterial Invasion: Linking Autophagy and Innate Immunity. <i>Current Biology</i> , 2010, 20, R106-R108.	1.8	13

#	ARTICLE	IF	CITATIONS
325	Pyroptosis â€“ a cell death modality of its kind?. <i>European Journal of Immunology</i> , 2010, 40, 627-630.	1.6	150
326	The IKK complex contributes to the induction of autophagy. <i>EMBO Journal</i> , 2010, 29, 619-631.	3.5	274
327	Targeting dendritic cell metabolism in cancer. <i>Nature Medicine</i> , 2010, 16, 858-859.	15.2	13
328	Surface-exposed calreticulin in the interaction between dying cells and phagocytes. <i>Annals of the New York Academy of Sciences</i> , 2010, 1209, 77-82.	1.8	97
329	Desirable cell death during anticancer chemotherapy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1209, 99-108.	1.8	70
330	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2010, 120, 457-71.	3.9	761
331	Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands. <i>Cancer Research</i> , 2010, 70, 490-500.	0.4	104
332	Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway. <i>Clinical Cancer Research</i> , 2010, 16, 3100-3104.	3.2	325
333	Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity. <i>Cancer Research</i> , 2010, 70, 855-858.	0.4	326
334	In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. <i>Cell Cycle</i> , 2010, 9, 2902-2907.	1.3	5
335	Integration of Host-Related Signatures with Cancer Cell-Derived Predictors for the Optimal Management of Anticancer Chemotherapy. <i>Cancer Research</i> , 2010, 70, 9538-9543.	0.4	27
336	Dendritic Cell-Derived Exosomes for Cancer Immunotherapy: What's Next?. <i>Cancer Research</i> , 2010, 70, 1281-1285.	0.4	278
337	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 700-728.	2.0	34
338	Decoding Cell Death Signals in Inflammation and Immunity. <i>Cell</i> , 2010, 140, 798-804.	13.5	482
339	Chemotherapy and radiotherapy: Cryptic anticancer vaccines. <i>Seminars in Immunology</i> , 2010, 22, 113-124.	2.7	183
340	Chemotherapy induces ATP release from tumor cells. <i>Cell Cycle</i> , 2009, 8, 3723-3728.	1.3	233
341	Phylogenetic conservation of the preapoptotic calreticulin exposure pathway from yeast to mammals. <i>Cell Cycle</i> , 2009, 8, 639-642.	1.3	23
342	Natural Killer Cell IFN- γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients. <i>Cancer Research</i> , 2009, 69, 3563-3569.	0.4	181

#	ARTICLE	IF	CITATIONS
343	Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. <i>Journal of Clinical Investigation</i> , 2009, 119, 2127-30.	3.9	51
344	Viral subversion of immunogenic cell death. <i>Cell Cycle</i> , 2009, 8, 860-869.	1.3	60
345	The Dendritic Cell-like Functions of IFN-Producing Killer Dendritic Cells Reside in the CD11b+ Subset and Are Licensed by Tumor Cells. <i>Cancer Research</i> , 2009, 69, 6590-6597.	0.4	26
346	Immunogenic cell death modalities and their impact on cancer treatment. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 364-375.	2.2	185
347	Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. <i>EMBO Journal</i> , 2009, 28, 578-590.	3.5	683
348	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 β -dependent adaptive immunity against tumors. <i>Nature Medicine</i> , 2009, 15, 1170-1178.	15.2	1,614
349	Immunogenic and tolerogenic cell death. <i>Nature Reviews Immunology</i> , 2009, 9, 353-363.	10.6	970
350	Witch Hunt against Tumor Cells Enhanced by Dendritic Cells. <i>Annals of the New York Academy of Sciences</i> , 2009, 1174, 51-60.	1.8	11
351	Disruption of the PP1/GADD34 complex induces calreticulin exposure. <i>Cell Cycle</i> , 2009, 8, 3971-3977.	1.3	38
352	Personalized immunotherapy: a siren myth?. <i>Personalized Medicine</i> , 2009, 6, 469-473.	0.8	0
353	The immunogenicity of tumor cell death. <i>Current Opinion in Oncology</i> , 2009, 21, 71-76.	1.1	101
354	Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15. <i>PLoS ONE</i> , 2009, 4, e4942.	1.1	352
355	Immunogenic cancer cell death: a key-lock paradigm. <i>Current Opinion in Immunology</i> , 2008, 20, 504-511.	2.4	271
356	Introduction: the immune response against dying cells. <i>Current Opinion in Immunology</i> , 2008, 20, 501-503.	2.4	12
357	Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1291-1300.	2.0	65
358	Killer dendritic cells: IKDC and the others. <i>Current Opinion in Immunology</i> , 2008, 20, 558-565.	2.4	35
359	Natural killer cell-directed therapies: moving from unexpected results to successful strategies. <i>Nature Immunology</i> , 2008, 9, 486-494.	7.0	265
360	Immunological aspects of cancer chemotherapy. <i>Nature Reviews Immunology</i> , 2008, 8, 59-73.	10.6	1,374

#	ARTICLE	IF	CITATIONS
361	Dendritic cells and innate defense against tumor cells. <i>Cytokine and Growth Factor Reviews</i> , 2008, 19, 79-92.	3.2	49
362	Molecular Interactions between Dying Tumor Cells and the Innate Immune System Determine the Efficacy of Conventional Anticancer Therapies. <i>Cancer Research</i> , 2008, 68, 4026-4030.	0.4	198
363	The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2. <i>Journal of Immunology</i> , 2008, 180, 6477-6483.	0.4	44
364	Regulatory T Cells Control Dendritic Cell/NK Cell Cross-Talk in Lymph Nodes at the Steady State by Inhibiting CD4+ Self-Reactive T Cells. <i>Journal of Immunology</i> , 2008, 180, 4679-4686.	0.4	78
365	CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?. <i>Clinical Cancer Research</i> , 2008, 14, 5242-5249.	3.2	104
366	The anticancer immune response: indispensable for therapeutic success?. <i>Journal of Clinical Investigation</i> , 2008, 118, 1991-2001.	3.9	520
367	<i>Trans</i>-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions. <i>Journal of Immunology</i> , 2008, 180, 7887-7897.	0.4	47
368	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. <i>Journal of Clinical Investigation</i> , 2008, 118, 3751-3761.	3.9	56
369	IL-18 Elicited Suppressor NK Cells with Immunoregulatory Functions. <i>Blood</i> , 2008, 112, 106-106.	0.6	1
370	Therapy-Induced Tumor Immunosurveillance Involves IFN-Producing Killer Dendritic Cells: Figure 1.. <i>Cancer Research</i> , 2007, 67, 851-853.	0.4	33
371	Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from "Silent" to Immunogenic. <i>Cancer Research</i> , 2007, 67, 7941-7944.	0.4	134
372	Interferon- β is produced by another player of innate immune responses: The interferon-producing killer dendritic cell (IKDC). <i>Biochimie</i> , 2007, 89, 872-877.	1.3	24
373	Calreticulin exposure dictates the immunogenicity of cancer cell death. <i>Nature Medicine</i> , 2007, 13, 54-61.	15.2	2,580
374	Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. <i>Nature Medicine</i> , 2007, 13, 1050-1059.	15.2	2,657
375	Ecto-calreticulin in immunogenic chemotherapy. <i>Immunological Reviews</i> , 2007, 220, 22-34.	2.8	183
376	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. <i>Immunological Reviews</i> , 2007, 220, 47-59.	2.8	491
377	Death, danger, and immunity: an infernal trio. <i>Immunological Reviews</i> , 2007, 220, 5-7.	2.8	17
378	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. <i>Journal of Molecular Medicine</i> , 2007, 85, 1069-1076.	1.7	68

#	ARTICLE	IF	CITATIONS
379	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 641-648.	2.0	1,104
380	Links between innate and cognate tumor immunity. <i>Current Opinion in Immunology</i> , 2007, 19, 224-231.	2.4	59
381	Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. <i>Cancer Genomics and Proteomics</i> , 2007, 4, 65-70.	1.0	11
382	The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. <i>Immunological Reviews</i> , 2006, 214, 229-238.	2.8	235
383	A novel dendritic cell subset involved in tumor immunosurveillance. <i>Nature Medicine</i> , 2006, 12, 214-219.	15.2	377
384	Cancer despite immunosurveillance: immunoselection and immunosubversion. <i>Nature Reviews Immunology</i> , 2006, 6, 715-727.	10.6	1,108
385	Apoptosis regulation in tetraploid cancer cells. <i>EMBO Journal</i> , 2006, 25, 2584-2595.	3.5	180
386	Selective Resistance of Tetraploid Cancer Cells against DNA Damage-Induced Apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2006, 1090, 35-49.	1.8	50
387	Dendritic cell derived-exosomes: biology and clinical implementations. <i>Journal of Leukocyte Biology</i> , 2006, 80, 471-478.	1.5	117
388	Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines. <i>Journal of Immunology</i> , 2006, 176, 2722-2729.	0.4	192
389	In vivo veritas. <i>Nature Biotechnology</i> , 2005, 23, 1372-1374.	9.4	19
390	IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes. <i>European Journal of Immunology</i> , 2005, 35, 2840-2850.	1.6	12
391	Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. <i>Journal of Experimental Medicine</i> , 2005, 202, 1691-1701.	4.2	1,224
392	BCR/ABL Promotes Dendritic Cell-Mediated Natural Killer Cell Activation. <i>Cancer Research</i> , 2005, 65, 6409-6417.	0.4	38
393	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor- β dependent manner. <i>Journal of Experimental Medicine</i> , 2005, 202, 1075-1085.	4.2	806
394	The potential of exosomes in immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 737-747.	1.4	42
395	Tumor cells convert immature myeloid dendritic cells into TGF- β -secreting cells inducing CD4+CD25+ regulatory T cell proliferation. <i>Journal of Experimental Medicine</i> , 2005, 202, 919-929.	4.2	676
396	The dialogue between natural killer cells and dendritic cells. <i>International Congress Series</i> , 2005, 1285, 169-176.	0.2	0

#	ARTICLE	IF	CITATIONS
397	The potential of exosomes in immunotherapy of cancer. <i>Blood Cells, Molecules, and Diseases</i> , 2005, 35, 111-115.	0.6	37
398	Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma. <i>Cancer Research</i> , 2004, 64, 2192-2198.	0.4	94
399	Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection. <i>Journal of Immunology</i> , 2004, 172, 2137-2146.	0.4	233
400	Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class II/Peptide Complexes to Dendritic Cells. <i>Journal of Immunology</i> , 2004, 172, 2126-2136.	0.4	424
401	IL-4 Confers NK Stimulatory Capacity to Murine Dendritic Cells: A Signaling Pathway Involving KARAP/DAP12-Trigging Receptor Expressed on Myeloid Cell 2 Molecules. <i>Journal of Immunology</i> , 2004, 172, 5957-5966.	0.4	67
402	Exosome-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 234-239.	2.0	113
403	Proteomic Analysis of Exosomes Secreted by Human Mesothelioma Cells. <i>American Journal of Pathology</i> , 2004, 164, 1807-1815.	1.9	318
404	Immune Response Against Dying Tumor Cells. <i>Advances in Immunology</i> , 2004, 84, 131-179.	1.1	104
405	Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. <i>Blood</i> , 2004, 103, 1966-1967.	0.6	45
406	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. <i>Journal of Clinical Investigation</i> , 2004, 114, 379-388.	3.9	248
407	Dendritic and Natural Killer Cells Cooperate in the Control/Switch of Innate Immunity. <i>Journal of Experimental Medicine</i> , 2002, 195, F9-F14.	4.2	240
408	Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. <i>Blood</i> , 2002, 100, 2554-2561.	0.6	56
409	Malignant effusions and immunogenic tumour-derived exosomes. <i>Lancet, The</i> , 2002, 360, 295-305.	6.3	822
410	Exosomes: composition, biogenesis and function. <i>Nature Reviews Immunology</i> , 2002, 2, 569-579.	10.6	4,401
411	ANTIGENPRESENTATION ANDT CELLSTIMULATION BYDENDRITICCELLS. <i>Annual Review of Immunology</i> , 2002, 20, 621-667.	9.5	1,577
412	Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. <i>European Cytokine Network</i> , 2002, 13, 17-27.	1.1	57
413	From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. <i>Current Opinion in Molecular Therapeutics</i> , 2002, 4, 372-81.	2.8	21
414	Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. <i>Nature Medicine</i> , 2001, 7, 297-303.	15.2	1,362

#	ARTICLE	IF	CITATIONS
415	Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells. <i>Journal of Immunology</i> , 2001, 167, 1795-1802.	0.4	65
416	Dendritic Cell Maturation Overrides H-2 ^d -Mediated Natural Killer T (Nkt) Cell Inhibition. <i>Journal of Experimental Medicine</i> , 2001, 194, 1179-1186.	4.2	71
417	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 199-206.	0.6	16
418	Molecular Characterization of Dendritic Cell-Derived Exosomes. <i>Journal of Cell Biology</i> , 1999, 147, 599-610.	2.3	950
419	Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. <i>Nature Medicine</i> , 1999, 5, 405-411.	15.2	984
420	Interleukin-12 Gene Therapy Prevents Establishment of SCC VII Squamous Cell Carcinomas, Inhibits Tumor Growth, and Elicits Long-term Antitumor Immunity in Syngeneic C3H Mice. <i>Laryngoscope</i> , 1998, 108, 261-268.	1.1	32
421	Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes. <i>Nature Medicine</i> , 1998, 4, 594-600.	15.2	1,908
422	Bone Marrow-Derived Dendritic Cells Serve as Potent Adjuvants for Peptide-Based Antitumor Vaccines. <i>Stem Cells</i> , 1997, 15, 94-103.	1.4	120
423	Murine Models of Cancer Cytokine Gene Therapy Using Interleukin-12. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 275-283.	1.8	34
424	IL-12-Engineered Dendritic Cells Serve as Effective Tumor Vaccine Adjuvants in Vivo. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 284-293.	1.8	85
425	Cytokine Gene Therapy of Cancer Using Interleukin-12: Murine and Clinical Trials. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 440-454.	1.8	70
426	Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. <i>European Journal of Immunology</i> , 1996, 26, 1335-1341.	1.6	135
427	IL-12 Gene Therapy Using Direct Injection of Tumors with Genetically Engineered Autologous Fibroblasts. University of Pittsburgh, Pittsburgh, Pennsylvania. <i>Human Gene Therapy</i> , 1995, 6, 1607-1624.	1.4	66
428	Construction and Characterization of Retroviral Vectors Expressing Biologically Active Human Interleukin-12. <i>Human Gene Therapy</i> , 1994, 5, 1493-1506.	1.4	131
429	Retroviral Vectors for Use in Human Gene Therapy for Cancer, Gaucher Disease, and Arthritis. <i>Annals of the New York Academy of Sciences</i> , 1994, 716, 72-89.	1.8	39